Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 9:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 10,545 matching trials from the live ClinicalTrials.gov search.
Filters: Cincinnati, Ohio Clear all
Active, not recruiting No phase listed Observational

Monitoring Response to Orkambi in Cystic Fibrosis Lung Disease by Inhaled Xenon MRI

NCT02848560
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Hyperpolarized Xenon
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 12 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 30, 2026, 9:24 PM EDT
Completed Phase 3 Interventional

Radiation Therapy in Treating Patients With Metastases to the Lymph Nodes in the Neck From an Unknown Primary Tumor

NCT00047125
View directory record Official record
Conditions
Carcinoma of Unknown Primary
Interventions
radiation therapy
Radiation
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
237
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 180 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Oct 30, 2026, 9:24 PM EDT
Completed No phase listed Observational

Effects of Transport on Patients With Traumatic Brain Injury

NCT01077089
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Not listed
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 25, 2013 · Synced Oct 30, 2026, 9:24 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

NCT02445391
View directory record Official record
Conditions
Estrogen Receptor Negative, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma
Interventions
Capecitabine, Carboplatin, Cisplatin
Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2031
U.S. locations
1023
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 634 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 30, 2026, 9:24 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of Belatacept (BMS-224818) With a Steroid-free Regimen in Subjects Undergoing Kidney Transplantation

NCT00455013
View directory record Official record
Conditions
Disorder Related to Renal Transplantation
Interventions
Thymoglobulin, Belatacept, Sirolimus, Tacrolimus, Mycophenolate Mofetil (MMF)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
11
States / cities
San Francisco, California • Denver, Colorado • Augusta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 30, 2026, 9:24 PM EDT
Completed Phase 1 Interventional

An Initial Study of AZD7325 in Adults With Fragile X Syndrome

NCT03140813
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
AZD7325 (High-Dose), AZD7325 (Low-Dose), Placebo oral capsule
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 8, 2021 · Synced Oct 30, 2026, 9:24 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Two Basal Insulins for Patients With Type 2 Diabetes (IOOY)

NCT00494013
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Insulin Lispro Protamine Suspension, Detemir
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
27
States / cities
Hueytown, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2009 · Synced Oct 30, 2026, 9:24 PM EDT
Active, not recruiting Phase 2 Interventional

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

NCT02465060
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma
Interventions
Adavosertib, Afatinib, Afatinib Dimaleate, Binimetinib, Biopsy Procedure, Biospecimen Collection, Capivasertib, Computed Tomography, Copanlisib, Copanlisib Hydrochloride, Crizotinib, Cytology Specimen Collection Procedure, Dabrafenib, Dabrafenib Mesylate, Dasatinib, Defactinib, Defactinib Hydrochloride, Echocardiography Test, Erdafitinib, Fexagratinib, Ipatasertib, Laboratory Biomarker Analysis, Larotrectinib, Larotrectinib Sulfate, Magnetic Resonance Imaging, Multigated Acquisition Scan, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-beta Inhibitor GSK2636771, Radiologic Examination, Radionuclide Imaging, Relatlimab, Sapanisertib, Sunitinib Malate, Taselisib, Trametinib, Trastuzumab, Trastuzumab Emtansine, Ulixertinib, Vismodegib
Drug · Procedure · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
6,452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1405
States / cities
Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 847 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 30, 2026, 9:24 PM EDT
Terminated Phase 1 Interventional

A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT05077423
View directory record Official record
Conditions
AML, Childhood
Interventions
CD33*CD3 BsAb
Drug
Lead sponsor
Y-mAbs Therapeutics
Industry
Eligibility
2 Years to 21 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
13
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 30, 2023 · Synced Oct 30, 2026, 9:24 PM EDT
Completed Phase 1 Interventional Results available

A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Participants

NCT02093923
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
DX-2930, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
12
States / cities
San Diego, California • Walnut Creek, California • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Oct 30, 2026, 9:24 PM EDT
Completed No phase listed Observational

A "Pre-Enrollment" Protocol for HIV-Infected Adolescents

NCT00000780
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years to 20 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
48
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 30, 2026, 9:24 PM EDT
Completed No phase listed Observational Results available

National Cardiogenic Shock Initiative

NCT03677180
View directory record Official record
Conditions
Cardiogenic Shock, Acute Myocardial Infarction, STEMI - ST Elevation Myocardial Infarction, NSTEMI - Non-ST Segment Elevation MI, Heart Attack
Interventions
Not listed
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
75
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 61 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 30, 2026, 9:24 PM EDT
Completed No phase listed Observational

Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)

NCT02503696
View directory record Official record
Conditions
Inflammatory Bowel Disease, Colorectal Neoplasms, Digestive System Diseases, Colonic Diseases, Colorectal Cancer
Interventions
Stool Collection Kit
Device
Lead sponsor
Exact Sciences Corporation
Industry
Eligibility
18 Years to 84 Years
Enrollment
697 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
27
States / cities
Dothan, Alabama • La Jolla, California • Mission Hills, California + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Oct 30, 2026, 9:24 PM EDT
Recruiting Phase 3 Interventional

Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy

NCT06628908
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
Suzetrigine, Placebo (matched to SUZ), Pregabalin, Placebo (matched to Pregabalin)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
76
States / cities
Anniston, Alabama • Birmingham, Alabama • Daphne, Alabama + 68 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 30, 2026, 9:24 PM EDT
Completed Phase 3 Interventional Results available

A Study to Look at Tapentadol Oral Solution in Children and Adolescents in Pain

NCT02081391
View directory record Official record
Conditions
Acute Pain
Interventions
Tapentadol oral solution 4 mg/mL, Tapentadol oral solution 20 mg/mL, Placebo
Drug · Other
Lead sponsor
Grünenthal GmbH
Industry
Eligibility
1 Day to 18 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
13
States / cities
Little Rock, Arkansas • Stanford, California • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 30, 2026, 9:24 PM EDT
Not listed Phase 2 Interventional Results available

An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children

NCT00791700
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Maraviroc
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
2 Years to 18 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
18
States / cities
Los Angeles, California • Orange, California • Wilmington, Delaware + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2020 · Synced Oct 30, 2026, 9:24 PM EDT
Completed No phase listed Observational

TFE Renal Cell Carcinoma: A Prospective Registry and Translational Research Initiative

NCT03630536
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
28 participants
Timeline
2018 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 30, 2026, 9:24 PM EDT
Completed Phase 2 Interventional

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week, Dose-Range-Finding Trial of YKP10811 Capsules Administered Once Daily to Subjects With Chronic Idiopathic Constipation

NCT01989234
View directory record Official record
Conditions
Chronic Idiopathic Constipation
Interventions
YKP10811, Placebo
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
69
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2014 · Synced Oct 30, 2026, 9:24 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

NCT05531565
View directory record Official record
Conditions
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
Interventions
Litifilimab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
62
States / cities
Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 30, 2026, 9:24 PM EDT
Active, not recruiting Phase 3 Interventional

Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients

NCT04824092
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma
Interventions
Tafasitamab, Lenalidomide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tafasitamab placebo, Lenalidomide placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
899 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
47
States / cities
Daphne, Alabama • Anaheim, California • Clovis, California + 44 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 30, 2026, 9:24 PM EDT
Recruiting No phase listed Observational

A Study to Develop a Blood-based Test for Aiding the Diagnosis/Prognosis of Traumatic Brain Injury in Adults and for Monitoring the Development of Secondary Events in Patients Diagnosed With Traumatic Brain Injury

NCT07455136
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Blood sample collection
Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
14
States / cities
Sacramento, California • San Francisco, California • Carmel, Indiana + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 30, 2026, 9:24 PM EDT
Completed Phase 4 Interventional Results available

Study of the Efficacy of Cloderm® Cream in the Treatment of Moderate Plaque Psoriasis

NCT01714544
View directory record Official record
Conditions
Psoriasis
Interventions
Cloderm Cream
Drug
Lead sponsor
Promius Pharma, LLC
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
5
States / cities
Cincinnati, Ohio • Portland, Oregon • Austin, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2014 · Synced Oct 30, 2026, 9:24 PM EDT
Recruiting No phase listed Observational

A Real-world Long-term Safety and Immunogenicity Study of Olipudase Alfa Therapy in Pediatric Patients Less Than 2 Years of Age With Acid Sphingomyelinase Deficiency (ASMD)

NCT06192576
View directory record Official record
Conditions
Niemann-Pick Diseases, Acid Sphingomyelinase Deficiency
Interventions
Olipudase alfa
Drug
Lead sponsor
Sanofi
Industry
Eligibility
Up to 2 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
6
States / cities
Chicago, Illinois • Cincinnati, Ohio • Columbus, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 30, 2026, 9:24 PM EDT
Completed Phase 3 Interventional Results available

JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis

NCT03796676
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Placebo, PF-04965842, PF04965842
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 17 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
52
States / cities
Birmingham, Alabama • Madera, California • Mission Viejo, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Oct 30, 2026, 9:24 PM EDT